3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Solid Tumors
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Cancers With NTRK, ROS1, or ALK Gene Fusions
1
Breast Neoplasms
1
Interventions
Irinotecan
8
Temozolomide
7
FANG vaccine
4
Topotecan
3
Cyclophosphamide
3
seclidemstat
2
eribulin
2
abemaciclib
2
Pemetrexed
2
Gemcitabine
2
trifluridine tipiracil drug combination
1
talazoparib
1
surufatinib
1
robatumumab
1
regorafenib
1
racotumomab
1
palbociclib
1
ganitumab
1
figitumumab
1
entrectinib
1
dinutuximab
1
copanlisib
1
cixutumumab
1
bempegaldesleukin
1
Vincristine
1
TB-403
1
PM 01183
1
PM 00104
1
Nivolumab
1
Leucovorin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma, Ewing
×
entrectinib
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA